Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers
Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...
Targeted Oncology2d
FDA Grants Orphan Drug Designation to CF33-hNIS in Cholangiocarcinoma
CF33-hNIS has gained FDA orphan drug designation for the treatment of cholangiocarcinoma and is currently being evaluated in ...
Business Insider5d
Immutep’s Efti in Combination with MSD’s KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer
E+P continues to have a comparable safety profile to pembrolizumab alone other than injection site reactions as expected with ...
Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term overall survival (OS) data ...
IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer
Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma ...
FierceBiotech7d
ESMO: IO Biotech's vaccine and Keytruda combo hits primary endpoint in phase 2 squamous cell carcinoma trial
Immune checkpoint inhibitors are the superheroes of cancer therapy. | Immune checkpoint inhibitors are the superheroes of ...
Science Daily7d
Experimental mRNA cancer vaccine shows potential for advanced stage cancer patients in Phase 1 trial
Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers. The investigational mRNA cancer immunotherapy is ...
The American Journal of Managed Care7d
Dr Jonathan Riess on the Potential of IO102-IO103, the Cancer Vaccine Landscape
In terms of combining IO102-IO103 with immune checkpoint inhibition, such as the PD-1 antibody pembrolizumab in our phase 2 trial that I presented at ESMO, the rationale is that subcutaneous injection ...
Experimental mRNA cancer vaccine shows potential for advanced stage cancer patients in Phase I trial
Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers.
New cancer jab that 'primes body to recognise and fight tumours'
The jab, known as mRNA-4359 and developed by Moderna, is aimed at people with advanced melanoma, lung cancer and other solid ...
Le Lézard11d
ChromaDex Announces Expansion of Pharmaceutical-Grade Niagen® IV and Injection Offerings to Additional Leading Wellness Clinics
ChromaDex Corp. , the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, is excited to announce the second wave of intravenous (IV) wellness clinics ...
Finanznachrichten12d
BioInvent International: BioInvent and Transgene to Present Promising Initial Phase 1/2a Data on Oncolytic Virus, BT-001, at ESMO 2024
No DLTs were observed with repeated intratumoral injections of BT-001 alone (in 18 patients) or in combination with pembrolizumab (in 6 patients). - Oncolytic virus BT-001 was shown to replicate and ...